RELEASE DATE: June 14, 2013
NOTICE OF INTENT TO APPLY DEADLINE: August 1, 2013
FULL APPLICATION DEADLINE: October 1, 2013
THIS RFA CONTAINS THE FOLLOWING INFORMATION:
Cystic Fibrosis Canada invites research grant applications to support knowledge translation platforms (core facilities) that will enhance the efficiency and foster collaborations within and among institutions with a strong existing base in CF research.
OBJECTIVES AND SCOPE
The objective of the Knowledge Translation Platforms program is to provide shared resources to support research to develop, test, and improve therapies for cystic fibrosis.
A knowledge translation platform is defined as a shared resource that provides essential tools, services, techniques, or instrumentation to enable users to conduct their funded individual research projects more efficiently and/or more effectively. These platforms must serve the needs beyond a single institution and should provide service at a regional/national/international level. A Knowledge Translation Platform is intended not only to serve as a support for the platform’s investigators and their projects, but primarily to function as a national resource to the CF community. Applicants should describe the extended research base that includes researchers who would use the services of the platform.
A research platform may be located in a single institution or in multiple institutions with complementary research bases.
The scope of this initiative is broad and is meant to support investigators involved in basic discovery to clinical research, thus this granting mechanism can be utilized for a variety of research platforms. However, the following research areas have been identified as priorities for this program:
Given this broad spectrum, applicants should clearly identify, explain and justify the specific focus of the proposed research platform. The applicants must define the value added that the platform support will provide to the CF field and demonstrate how it will fill an unmet need for the Canadian or international CF research community at large.
It is expected that applicants will have a substantial amount of relevant research activity at their institution and will explain how CF research can be expanded and enhanced by the support requested under this program.
The application should outline the scientific leadership for the proposed research platform and describe an administrative structure that maximizes efficiency through program planning, monitoring, maintenance, accountability and a transparent mechanism for prioritizing access. The platforms should address knowledge and technology transfer and should promote the platforms accomplishments within and beyond the institution.
Since it was established in 1960, Cystic Fibrosis Canada has developed a strong research program to search for a cure, or an effective control for CF -- and its track record has been remarkable. Many of the milestones on the road to a cure have been achieved by CF researchers across Canada.
At the same time, persons with CF continue to be gravely burdened in their quality of life as they must spend several hours, every day throughout their lifetimes, following medically prescribed treatment to delay the onset of symptoms, and to slow the progression of disease.
Cystic Fibrosis Canada is undertaking a transformational initiative to address the challenges that currently are standing in the way of translating basic research discoveries into novel therapies for CF patients. One of the major barriers on the road to drug development is access to centralized research platforms, including CF animal models, primary cells, high throughput screens, functional assays, and tissue banks. The Knowledge Translation Platforms will build upon Cystic Fibrosis Canada’s sustained investment in CF discovery research and will help support the infrastructure required for the ‘pipeline’ of CF therapeutics development.
Knowledge Translation Platforms are part of an integrated program of cystic fibrosis research and will provide increased, cost-effective collaboration among multidisciplinary teams of investigators to tackle difficult and complex problems in CF.
FUNDS AVAILABLE AND DURATION OF PROJECT
Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. For 2014/2015, Cystic Fibrosis Canada has allocated up to $150,000 per annum per proposal. The total amount awarded and the number of grants awarded will depend upon the number, quality, duration, and costs of the applications received.
The funding support is for up to five years of funding. In future continuations of the RFA, non-competitive renewal applications will be accepted. Progress reports describing research collaborations, including proof/documentation of collaborating and publishing with other CF researchers, will be required every two years for formal evaluation and continuation of funding.
The anticipated award start date is April 1, 2014 (at the earliest). Payments will be made in quarterly installments thereafter. Although the financial plans of the Cystic Fibrosis Canada provide support for this program, awards pursuant to this RFA are contingent upon the availability of funds, and approval by its Board of Directors.
These funds may be supplemented by partner organizations, institutions, industry or other sources.
Eligibility criteria for all Cystic Fibrosis Canada research funding programs apply. Please refer to the Grants and Awards Guide regarding the eligibility requirements for individuals and institutions.
A single institution may have more than one Knowledge Translation Platform grant but the platforms must address distinctly different research resources.
Funding may be used to support:
The application process is comprised of two steps: 1. Notice-of-Intent to Apply and 2. Full Application.
1. Notice-of-Intent to Apply
In the first stage of the application process, the applicant is required to submit a Notice-of-Intent to Apply. The NOI form is available on Cystic Fibrosis Canada’s website.
The Notice-of-Intent to Apply should include:
Please submit ONE signed Notice-of-Intent to Apply by email (as a PDF attachment).
The deadline for receipt of the Notice-of-Intent to Apply is Thursday, August 1, 2013 by 5:00 PM EDT.
2. Full Application
All applicants will be required to submit a full application. The Application Form will be available on Cystic Fibrosis Canada’s website.
The deadline for receipt of the full application is Tuesday, October 1, 2013. Completed applications and all supporting materials will be accepted only if hand-delivered to Cystic Fibrosis Canada’s office by 5:00 p.m. EDT on October 1st OR courier-marked on/before midnight on the deadline day of October 1st. Applications sent by courier must have guaranteed next-business day delivery.
The application should include the following components:
Evidence of partnership is encouraged, but is not required. Examples would include partnerships with industry, Networks of Centres of Excellence and other networks, and access to core facilities established by other networks. Emphasis will be placed on building partnerships and attracting supplementary funding from such partners and from other funding agencies. This may be in the form of direct funding or « in kind » support.
Applicants will be expected to provide letters of commitment, or commitment in principle, from partners and other funding sources, when submitting a full application for funding.
EVALUATION OF APPLICATIONS AND REVIEW CRITERIA
Upon receipt, the application will be reviewed for completeness by the Cystic Fibrosis Canada and evaluated by an Expert Review Panel. The Expert Review Panel will include additional individuals, from Canada and/or abroad, with special expertise in cystic fibrosis research platforms.
Applications will be evaluated as a single, integrated entity. While each research component included in the application must be meritorious, it is critical to demonstrate that the Knowledge Translation Platform brings added value, in terms of the approach to the improved care for CF patients, and the speed and efficiency with which new knowledge will be generated and translated.
Applications will be evaluated on the following criteria:
Please note that the Expert Review Panel also reserves the option to accept or reject specific components of the proposed research platform.
We encourage enquiries concerning this RFA and welcome the opportunity to answer questions from potential applicants. Enquiries may fall into two areas: scientific/research, and financial or grants management issues:
Direct your questions to:
Program Director, Research Funding
Cystic Fibrosis Canada
2221 Yonge Street, Suite 601
Toronto, ON M4S 2B4
Telephone: (416) 485-9149 or 1 800 378-2233 ext. 237
FAX: (416) 485-0960
RECEIPT AND REVIEW SCHEDULE
Notice of Intent to Apply Form Receipt Date: August 1, 2013
Full Application Form Receipt Date: October 1, 2013
Peer Review Date: November 2013
Award Notification Date: February 2014
Earliest Anticipated Start Date: April 1, 2014
CYSTIC FIBROSIS CANADA POLICIES
All groups intending to apply should read Cystic Fibrosis Canada’s Grants and Awards Guide for policies regarding research involving human subjects, stem cells, animal subjects, biohazardous materials; and policies regarding patents and royalties, publications and publicity.